Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASCO20: Maintenance Metronomic Capecitabine Extends DFS in TNBC

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form